凯赛生物上市发行费用合计28,062.72万元(不含增值税金额)，其中中信证券股份有限公司获得承销及保 荐费用26,229.34万元。 2022年7月12日，凯赛生物公告称，拟每10股派息(税前)4.5元，转增4股。股权登记日为2022年7月19 日，除权除息日为2022年7月20日。 2024年年报显示，凯赛生物的实际控制人为XIUCAI LIU(刘修才)、XIAOWEN MA、CHARLIE CHI LIU 系美籍华人。 中国经济网北京1月15日讯凯赛生物(688065.SH)今日收报57.62元，跌幅3.60%。目前该股处于破发状 态。 凯赛生物于2020年8月12日在上交所科创板上市，公开发行股份总数为4,166.8198万股，占发行后股份总 数的10.00%，发行价格为133.45元/股，保荐人(主承销商)为中信证券股份有限公司，保荐代表人为先卫 国、黄艺彬。 上市首日，凯赛生物盘中最高价198元，为该股上市以来最高价。 凯赛生物上市募集资金总额556,062.10万元，募集资金净额为527,999.38万元。凯赛生物最终募集资金净 额比原计划多58,108.38万元。凯赛生物2020年8月11日披 ...

Market Overview - The chemical products sector experienced a decline of 0.55% on January 14, with Chenghe Technology leading the losses [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index rose to 14248.6, up 0.56% [1] Top Gainers in Chemical Sector - Qicai Chemical (300758) saw a significant increase of 20.01%, closing at 16.85 with a trading volume of 524,100 shares and a turnover of 832 million [1] - Changhua Chemical (301518) rose by 12.77%, closing at 44.60 with a trading volume of 124,200 shares and a turnover of 519 million [1] - Demei Chemical (002054) increased by 9.99%, closing at 8.81 with a trading volume of 420,300 shares and a turnover of 360 million [1] Top Losers in Chemical Sector - Chenghe Technology (688625) declined by 5.79%, closing at 58.71 with a trading volume of 88,500 shares and a turnover of 525 million [2] - Duofuduo (002407) fell by 4.31%, closing at 31.55 with a trading volume of 1,265,100 shares and a turnover of 404.6 million [2] - Kaisa Bio (688065) decreased by 3.97%, closing at 59.77 with a trading volume of 158,000 shares and a turnover of 965 million [2] Capital Flow Analysis - The chemical products sector experienced a net outflow of 1.757 billion from institutional investors, while retail investors saw a net inflow of 1.333 billion [2] - The top stocks with significant net inflows from retail investors include Qicai Chemical (300758) with a net inflow of 256 million [3] - Demei Chemical (002054) also had a notable net inflow of 108 million from retail investors [3]

Core Viewpoint - Biomanufacturing is identified as a key future industry in China's 14th Five-Year Plan, expected to create a market worth trillions in the next decade, driven by advancements in technology and policy support [2][5]. Group 1: Industry Overview - The biomanufacturing industry in China is nearing a total scale of 1 trillion yuan, with fermentation capacity accounting for over 70% of the global total [2][4]. - Shenzhen has become a hub for biomanufacturing, with 40% of newly established companies in this sector located there in the past three years, showcasing a significant industry clustering effect [4]. - The industry is supported by a comprehensive system of policy, funding, and technological advancements as outlined in the 14th Five-Year Plan [5]. Group 2: Key Enterprises - The article identifies 100 core enterprises in biomanufacturing, spanning the entire industry chain from upstream technology development to downstream commercial applications [7]. - Notable companies include: - Huada Technology, a leader in gene sequencing technology [17]. - Kaisa Biotech, which has achieved over 80% market share in the global long-chain dicarboxylic acid market [21]. - WuXi Biologics, representing China's capabilities in the global biopharmaceutical industry [27]. Group 3: Upstream Innovations - The upstream sector focuses on providing essential tools and technologies for research and production, with a shift towards domestic innovation and smart integration [16]. - Key trends include the localization of critical tools and the rise of AI-driven platform companies that enhance research efficiency [16][17]. - Over 75% of the 20 identified upstream enterprises are private, indicating a vibrant innovation landscape [16]. Group 4: Midstream Developments - The midstream sector is characterized by a dual structure of "upgraders" and "disruptors," with companies like Meihua Biotech and Chuaning Biotech leading in traditional fermentation while others like Kaisa Biotech innovate with new bioproducts [20][21]. - This segment contains the highest number of enterprises, with 40 out of the 100 identified companies, emphasizing the importance of production capacity and cost control [20]. Group 5: Downstream Applications - The downstream sector serves as a critical market for biomanufacturing, focusing on medical, consumer, and agricultural applications [25]. - Companies like Muyuan Foods exemplify the cost-saving potential of biomanufacturing in agriculture, while WuXi Biologics and Kelaiying represent the pharmaceutical sector's output capabilities [26][27]. - Future trends indicate a broadening of applications into new areas such as biobased textiles and environmental remediation [27].

Market Overview - The chemical products sector experienced a decline of 0.29% on January 13, with Qiaoyuan Co. leading the drop [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Top Performers - Huaheng Biological (688639) saw a significant increase of 13.79%, closing at 41.34 with a trading volume of 419,600 shares and a transaction value of 1.721 billion [1] - Chenghe Technology (688625) rose by 12.29%, closing at 62.32 with a trading volume of 109,000 shares and a transaction value of 672 million [1] - Kaisa Biological (688065) increased by 12.14%, closing at 62.24 with a trading volume of 177,800 shares [1] Underperformers - Qiaoyuan Co. (301286) fell by 8.67%, closing at 47.41 with a trading volume of 53,000 shares and a transaction value of 258 million [2] - Hangqing Co. (002430) decreased by 6.99%, closing at 32.06 with a trading volume of 311,600 shares [2] - Taihe Technology (300801) dropped by 6.72%, closing at 30.39 with a trading volume of 173,200 shares [2] Capital Flow - The chemical products sector saw a net outflow of 642 million from institutional investors and 357 million from retail investors, while retail investors had a net inflow of 999 million [2] - The capital flow data indicates a mixed sentiment among different investor types within the sector [2] Individual Stock Capital Flow - Duoliangduo (002407) had a net inflow of 224 million from institutional investors, while it experienced a net outflow of 1.09 billion from retail investors [3] - Wanhu Chemical (600309) saw a net inflow of 189 million from institutional investors, with a net outflow of 76.596 million from retail investors [3] - Yahua Group (002497) had a net inflow of 154 million from institutional investors, while retail investors experienced a net outflow of 17.488 million [3]

数据宝统计，截至14:32，凯赛生物成交额10.01亿元，创2020年8月14日以来新高。最新股价上涨 12.36%，换手率2.80%。上一交易日该股全天成交额为3.99亿元。 （文章来源：证券时报网） 据天眼查APP显示，上海凯赛生物技术股份有限公司成立于2000年11月24日，注册资本72128.9794万人 民币。（数据宝） ...

Group 1 - The chemical sector is experiencing a rebound, with the chemical ETF (516020) showing a significant increase, reaching a maximum intraday gain of 1.56% and closing up by 0.89% [1] - Key stocks in the sector include Kasei Bio, which surged by 12.54%, and Salt Lake Co., which rose by 7.13%, among others [1][2] - Recent capital inflow into the chemical sector has been strong, with the chemical ETF accumulating a net subscription of 560 million yuan over the last five trading days and over 910 million yuan in the last ten days [2] Group 2 - The Producer Price Index (PPI) for industrial products decreased by 1.9% year-on-year in December 2025, with a month-on-month increase of 0.2%, indicating a narrowing decline compared to the previous month [3] - The chemical industry is expected to undergo a revaluation, as its industry position and profit levels do not align, with potential recovery in profitability anticipated [3] - The chemical sector is at a new starting point of supply-demand rebalancing, influenced by policies aimed at reshaping competition and advancements in new production capabilities [3] Group 3 - The chemical ETF (516020) tracks the CSI segmented chemical industry theme index, with nearly 50% of its holdings concentrated in large-cap leading stocks, providing an opportunity for investors to capitalize on strong performers [4] - Investors can also access the chemical ETF through linked funds, enhancing investment efficiency in the chemical sector [4]

Investment Rating - The industry investment rating is "Recommended" (maintained) [1] Core Insights - The new materials sector is a crucial direction for the chemical industry, currently experiencing rapid growth in downstream demand. With policy support and technological breakthroughs, domestic new materials are expected to accelerate their long-term growth. The report emphasizes that "one generation of materials leads to one generation of industries," highlighting the foundational nature of the new materials industry as the material basis for other industries [5][15]. Summary by Relevant Sections 1. Electronic Information Sector - Focus on semiconductor materials, display materials, and 5G materials [6] - Recent developments include NVIDIA's announcement of its new AI supercomputing platform, Vera Rubin, which has entered full production. The platform features six independent chips, with the Rubin GPU achieving a peak computing power of 50 Petaflops and a training performance 3.5 times that of its predecessor [7][37]. 2. Aerospace Sector - Focus on PI films, precision ceramics, and carbon fiber [8] - The successful acquisition of a production license for the AS700 manned airship marks a significant milestone for China's aerospace industry, indicating a shift towards standardized and commercialized production [9][10]. 3. New Energy Sector - Focus on photovoltaics, lithium-ion batteries, proton exchange membranes, and hydrogen storage materials [10] - A notable development is the introduction of the world's first all-solid-state battery by a Finnish startup, set to enter OEM mass production [11]. 4. Biotechnology Sector - Focus on synthetic biology and scientific services [12] - Beijing's economic development zone has announced measures to support the innovation and development of the synthetic biology manufacturing industry, aiming to establish a globally influential industry cluster by 2028 [13]. 5. Energy Conservation and Environmental Protection Sector - Focus on adsorbent resins, membrane materials, and biodegradable plastics [14] - The Guangxi government has issued a plan for green mine construction, aiming for over 90% of large and medium-sized mines to meet green standards by the end of 2028 [15]. 6. Industry Rating and Investment Strategy - The new materials sector is expected to benefit from the catalytic effects of downstream application sectors, gradually entering a prosperous cycle, thus maintaining a "Recommended" rating for the new materials industry [15].

Group 1 - The chemical sector continues to show strong performance, with the Chemical ETF (516020) experiencing a maximum intraday increase of 3.83% and closing up 3.38% [1][8] - Key stocks in the sector include Junzheng Group, which surged by 9.48%, and other notable performers such as Xingfa Group and Hengli Petrochemical, both rising over 8% [1][8] - The basic chemical sector attracted significant capital inflow, with a net inflow of 12.4 billion yuan on the day, ranking second among 30 CITIC primary industries [11][12] Group 2 - The Chemical ETF (516020) has seen a total net subscription of 352 million yuan over the past five trading days, indicating strong investor interest [3][9] - PVC futures contracts rose over 3% in a single day, with a cumulative increase of over 15% since mid-December [10] - Analysts predict that by 2026, the petrochemical industry will undergo a supply-side clearing, leading to a recovery in demand for specific segments like PX and PTA [10] Group 3 - The valuation of the chemical sector remains reasonable, with the Chemical ETF's underlying index price-to-book ratio at 2.65, positioned at the 52.45 percentile over the past decade [10] - The chemical industry is currently at a cyclical bottom, with potential for recovery driven by demand stimulation policies and ongoing export growth [12] - The Chemical ETF (516020) provides an efficient way to invest in the sector, with nearly 50% of its holdings in large-cap leading stocks, allowing investors to capitalize on strong market trends [12]

Core Viewpoint - The chemical sector is experiencing a significant rally, with the chemical ETF (516020) showing strong performance and individual stocks within the sector also seeing substantial gains [1][3]. Group 1: Market Performance - The chemical ETF (516020) opened with a rise and maintained high volatility, reaching a maximum intraday increase of 3.83% and closing up by 3.15% [1]. - Key stocks in the sector, such as Hengli Petrochemical, surged over 8%, while others like Xingfa Group, Kaisa Bio, and Junzheng Group increased by more than 7% [1]. - The basic chemical sector attracted significant capital, with a net inflow of 12.4 billion yuan on the day, ranking second among 30 major sectors [3]. Group 2: Price Movements and Profit Expectations - In late December, the price of paraxylene (PX) rose significantly, with futures increasing by over 800 yuan/ton and spot prices up by approximately 340 yuan/ton [3]. - The rise in PX prices is expected to enhance profit expectations for refining companies, leading to a bullish sentiment in the stock market [3]. - Major changes among leading companies during a period of industry downturn may present opportunities for recovery [3]. Group 3: Future Outlook - China Galaxy Securities forecasts a negative growth in capital expenditure for the chemical industry in 2024, with supply-side contraction expected due to the "anti-involution" trend and the acceleration of the elimination of outdated capacity [3]. - The "14th Five-Year Plan" emphasizes expanding domestic demand, which, combined with the onset of a U.S. interest rate cut cycle, is anticipated to open up demand for chemical products [3]. - A dual bottom in supply and demand is expected to be established, with strong policy catalysts potentially leading to a cyclical upturn in the chemical industry by 2026, marking a transition from valuation recovery to earnings growth [3]. Group 4: Investment Opportunities - Investors may consider the chemical ETF (516020) for efficient exposure to the sector, as it tracks the CSI sub-industry index and covers various segments of the chemical industry [4]. - Nearly 50% of the ETF's holdings are concentrated in large-cap leading stocks, such as Wanhua Chemical and Salt Lake Industry, providing opportunities for strong performance [4]. - The remaining 50% of the ETF's holdings include leading stocks in segments like phosphate fertilizers, fluorine chemicals, and nitrogen fertilizers, allowing for comprehensive investment in the chemical sector [4].

Core Viewpoint - The chemical sector is experiencing significant gains, with the chemical ETF (516020) showing a price increase of 3.15% as of the latest report, following a peak increase of 3.83% during the trading session [1][7]. Group 1: Market Performance - The chemical ETF (516020) opened with a strong upward trend and has maintained high volatility, reflecting the overall positive performance of the chemical sector [1][7]. - Key stocks in the sector, such as Hengli Petrochemical, surged over 8%, while others like Xingfa Group, Kasei Biotech, and Junzheng Group saw increases exceeding 7% [1][7]. Group 2: Capital Inflows - The basic chemical sector attracted substantial capital, with a net inflow of 12.469 billion yuan on the day, ranking second among 30 major sectors [9][10]. - Over the past 60 days, the basic chemical sector has accumulated a total net inflow of 236.9 billion yuan, placing it third among the 30 major sectors [9][10]. Group 3: Price Movements and Market Sentiment - In late December, the price of paraxylene (PX) increased significantly, with futures rising over 800 yuan per ton and spot prices up approximately 340 yuan per ton [10]. - Analysts from Dongfang Securities noted that the price increase of PX, a key product in integrated refining projects, has led to improved profit expectations for refining companies, thereby stimulating stock market activity [10]. Group 4: Future Outlook - China Galaxy Securities predicts a negative growth in capital expenditure for the chemical industry in 2024, with supply expected to contract due to the "anti-involution" trend and the accelerated elimination of outdated overseas capacities [11]. - The "14th Five-Year Plan" emphasizes expanding domestic demand, which, combined with the onset of a U.S. interest rate cut cycle, is expected to open up demand space for chemical products [11]. - The firm anticipates that the chemical industry may reach a cyclical turning point by 2026, transitioning from valuation recovery to earnings growth, referred to as a "Davis double play" [11].